Thursday, March 27, 2008 12:29:44 PM
re hysterectomy
i think i put to rest the notion that hysterectomy is "benign" by any reasonable definition of the word, but just flipping through the latest issue of obstetrics and gynecology there is an article on incidence of pain following a pfannensteil incision (the most commonly used incision for pelvic cases). at an average of 2 years follow up:
- 1/3 of pts report chronic incisional pain
- in 7% of patients this pain is graded as moderate to severe
- 8.9% report pain of an intensity sufficient to impair daily activities
these stats are somewhat surprising to me - and i bet this potential complication of pelvic surgery is underappreciated by the broader medical community as well (largely because of how often pts are lost to follow up)
PS: i know this has no real relevance to rprx as an investment, but just thought it was an interesting stat to share
i think i put to rest the notion that hysterectomy is "benign" by any reasonable definition of the word, but just flipping through the latest issue of obstetrics and gynecology there is an article on incidence of pain following a pfannensteil incision (the most commonly used incision for pelvic cases). at an average of 2 years follow up:
- 1/3 of pts report chronic incisional pain
- in 7% of patients this pain is graded as moderate to severe
- 8.9% report pain of an intensity sufficient to impair daily activities
these stats are somewhat surprising to me - and i bet this potential complication of pelvic surgery is underappreciated by the broader medical community as well (largely because of how often pts are lost to follow up)
PS: i know this has no real relevance to rprx as an investment, but just thought it was an interesting stat to share
Recent RPRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:58:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:55:58 PM
- Form 13F-NT - Quarterly report filed by institutional managers, Notice • Edgar (US Regulatory) • 04/01/2026 08:41:34 PM
- Royalty Pharma signs $500M co-development agreement with J&J • IH Market News • 03/30/2026 12:28:19 PM
- Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases • GlobeNewswire Inc. • 03/30/2026 11:15:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/23/2026 08:43:18 PM
- Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence • GlobeNewswire Inc. • 03/23/2026 11:15:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 09:12:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/18/2026 10:02:29 PM
- Royalty Pharma Announces Expansion of Leadership Team • GlobeNewswire Inc. • 03/17/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:11:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 09:52:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:26:17 PM
- Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform • GlobeNewswire Inc. • 03/02/2026 12:00:00 PM
- Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing • GlobeNewswire Inc. • 03/02/2026 11:10:00 AM
- Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing • GlobeNewswire Inc. • 03/02/2026 11:01:00 AM
- Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference • GlobeNewswire Inc. • 02/26/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 09:08:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 10:06:45 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/20/2026 09:27:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:03:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:02:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:02:26 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 02:04:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 12:37:12 PM
